Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyvanse for Cognitive Difficulties in Menopausal Women
NCT01977625Phase 4Completed
- Sponsor
- University of Pennsylvania
- Start
- Dec 2011
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of lisdexamfetamine in cognitive impairment (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Blood Oxygen Level Dependent Signal at 10 weeks. Started Dec 2011; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT01977625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01977625.